This release is intended for distribution in Canada only and is not to be distributed to United States newswire services or disseminated in the United States.

TORONTO, Ontario – January 27, 2006: NeuroMedix Inc. (“NeuroMedix”) is pleased to announce that its common shares will commence trading on the TSX Venture Exchange under the symbol “NMX” on Monday, January 30, 2006 upon market opening.

About NeuroMedix:

NeuroMedix is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease, multiple sclerosis and Parkinson’s disease. Our therapeutic drug candidates are based on research from a team of leading experts in the field of neuroinflammation and have been demonstrated to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. Based on these findings, NeuroMedix is pursuing the development of a lead compound for the prevention of Alzheimer's disease in humans.

For further information on NeuroMedix, visit www.neuromedixinc.com or contact:

Mark Pearson, PhD.
Chief Executive Officer
NeuroMedix Inc.
mark@neuromedixinc.com

Catherine Auld, CA
Chief Financial Officer
NeuroMedix Inc.
cathy@neuromedixinc.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.